羰基还原酶产生菌Candida ontarioensis制备(R)-2-氯-1-(3-氯苯基)乙醇

从实验室保藏的菌株中筛选获得Candida sp.PT2A,并通过18S rRNA鉴定为安大略假单胞菌Candida on-tarioensis。对C.ontarioensis不对称还原合成(R)-2-氯-1-(3-氯苯基)乙醇的发酵产酶条件和转化条件进行优化,确定了最适的发酵产酶条件和转化条件:温度30℃,初始pH 6.5,摇床转速180 r/min,菌体质量浓度200 g/L。采用2-氯-1-(3-氯苯基)乙酮质量浓度为10 g/L时,还原反应72 h,(R)-2-氯-1-(3-氯苯基)乙醇的e.e.值为99.9%,产率为99%;底物质量浓度提高至30 g/L时,产率下降为84.3%。采用十六烷基三甲基溴化铵(CTAB)对C.ontarioensis细胞进行通透性处理(CTAB g/L,4℃下处理20 min),在30 g/L底物下反应24 h,产物的e.e.和产率分别达到99.9%和97.5%。     

ω-转氨酶定点突变及生物催化制备(S)-1-(2-氟苯基)乙胺

(S)-1-(2-氟苯基)乙胺是药物合成中重要的手性砌块,ω-转氨酶被认为是一种催化制备手性胺的绿色、高效催化剂。本研究通过基因挖掘手段从NCBI数据库获得来源于氧化亚铁假古布尔班克氏菌(Pseudogulbenkiania ferrooxidans)的新型ω-转氨酶(PfTA),对其进行半理性设计,得到一株酶活性提高的突变株Y168R/R416Q,其可高选择性催化2-氟苯乙酮合成(S)-1-(2-氟苯基)乙胺,反应10 h后产率达83.58%,对映体过量值(enantiomeric excess, ee)大于99%。与野生型(wild type, WT)相比,突变株Y168R/R416Q的比酶活提高了11.65倍,达到47.04 U/mg,催化效率k_cat/K_m提高20.9倍。分子对接和结构模拟分析表明,突变后酶的活性口袋拓宽,底物2-氟苯乙酮进入酶活性中心的空间位阻减小,从而有效提高了突变体的催化效率。     

固定化细胞生物催化制备(S)-苯基乙二醇的研究

采用海藻酸钙固定化细胞方法能有效提高近平滑假丝酵母催化(RS)-苯基乙二醇(S-PED)去消旋化反应的稳定性,在优化反应条件下,固定化细胞催化批次由游离细胞的2次提高至6次,产物可保持高光学纯度(>95%)、高产率(>85%)。与化学合成液晶掺杂剂S-1011的理化特性对比结果表明,生物催化法制备获得的(S)-PED能够替代化学法制备的相同产品。     

(S)-羰基还原酶Ⅱ与葡萄糖脱氢酶共催化高效合成(S)-苯乙二醇

【目的】通过优化获得最佳酶活配比,设计近平滑假丝酵母(Candida parapsilosis)CCTCC M203011的(S)-羰基还原酶Ⅱ与枯草芽孢杆菌(Bacillus sp.)YX-1葡萄糖脱氢酶在大肠杆菌中的共表达体系,实现重组菌高效催化2-羟基苯乙酮,合成(S)-苯乙二醇。【方法】分别从重组大肠杆菌中纯化了(S)-羰基还原酶Ⅱ和葡萄糖脱氢酶,研究了2种酶共催化2-羟基苯乙酮的最佳酶活比例,最适催化温度和pH,由此构建(S)-羰基还原酶Ⅱ和葡萄糖脱氢酶的共表达体系。【结果】(S)-羰基还原酶Ⅱ的比酶活力为1.3 U/mg,葡萄糖脱氢酶的比酶活力为13.5 U/mg。在总酶活力为1 U时,(S)-羰基还原酶Ⅱ和葡萄糖脱氢酶共催化体系中,确定了2种酶的最佳比例在1∶1到5∶1(U/U)之间,最适反应温度为30℃,pH为7.0。在此基础上构建了(S)-羰基还原酶Ⅱ和葡萄糖脱氢酶基因比为1∶1的共表达体系,共表达重组菌破碎上清液中(S)-羰基还原酶Ⅱ和葡萄糖脱氢酶酶活分别为0.76 U/mg和0.73 U/mg,两者的酶活比例为1∶1。在上述确定的最适催化条件下,其催化10 g/L 2-羟基苯乙酮,产物(S)-苯乙二醇的光学纯度和得率均高达99%以上。与仅含有(S)-羰基还原酶Ⅱ的重组大肠杆菌相比,共表达体系转化产物(S)-苯乙二醇的得率明显提高,且转化时间由原来的24 h缩短为13 h。【结论】通过确定(S)-羰基还原酶Ⅱ和葡萄糖脱氢酶最佳酶活配比,为构建手性催化的靶酶和辅酶再生酶共表达体系,为实现手性化合物的高效制备提供了研究基础。     

基于金属有机框架的固定化酰胺酶制备及催化合成(S)-4-氟苯甘氨酸

以微水溶剂热法快速制备的稳定锆基金属有机框架为载体,戊二醛为交联剂,采用交联法对酰胺酶进行固定化,考察了不同条件对酰胺酶固定化效率的影响.结果 表明,戊二醛浓度为1.0％、交联时间为180 min、载体与酶的质量比为8∶1,固定化效率最佳,固定化酶活力回收率达86.4％,蛋白负载量达115.3 mg/g.固定化酶最适温...     

芽胞杆菌(Bacillus sp.)YX-1耐有机溶剂葡萄糖脱氢酶的基因克隆与酶学性质

[目的] 从芽胞杆菌(Bacillus sp.)YX-1基因组中克隆出一种有机溶剂耐受型的葡萄糖脱氢酶基因,实现了该基因在大肠杆菌中的高效表达,研究了重组蛋白的酶学性质.[方法] 依据芽胞杆菌属中葡萄糖脱氢酶氨基酸序列的保守性,设计合理引物,钓取来源于Bacillus sp.YX-1的葡萄糖脱氢酶基因,构建诱导型表达载体pET28a-gdh,于大肠杆菌中进行表达.镍柱亲和层析法纯化重组蛋白,考察了重组蛋白的酶学性质.[结果] 葡萄糖脱氢酶基因全长为786 bp,编码261个氨基酸.酶学研究结果表明:该酶最适反应温度为45℃,最适pH值为8.0;具有良好的有机溶剂耐受性,于50％的辛烷、环己烷、癸烷中室温放置1h后,酶活仍能保持90％以上;具有较宽的底物谱,对多种糖均具有一定的催化活性,其中催化D-葡萄糖的活力最高,产生还原型辅酶因子;对辅酶NADH和NADPH具有相似的依赖性,对NAD+和NADP+的催化比活分别为8.37 U/mg和8.62 U/mg.[结论]利用生物信息学成功地挖掘出Bacillus sp.YX-1一种耐有机溶剂的葡萄糖脱氢酶,为氧化还原酶在有机相反应中的的辅酶再生循环提供了新型的生物催化剂.     

生物催化3-(4-氯苯基)-戊二腈去对称性水解合成光学纯巴氯芬的关键前体

研究了利用生物催化剂制备(S)-4-氰基-3-(4-氯苯基)-丁酸.以3-(4-氯苯基)-戊二腈为底物,采用苯酚-次氯酸钠法对实验室保藏的菌株进行筛选,得到一株产物立体选择性较高的菌株赤霉菌Gibberella intermedia WX12,并对其催化特性和发酵条件进行了初步研究.以30 g/L的乳糖和20 g/L的蛋白胨分别为碳、氮源,发酵培养96 h,收集的菌体在50 mmol/L磷酸缓冲液(pH 8.0)中30℃催化反应24 h,将3-(4-氯苯基)-戊二腈转化为4-氰基-3-(4-氯苯基)-丁酸,产率为90％.将产物化学转化为巴氯芬,手性HPLC分析表明水解产物构型是(S),其对映异构体过量值ee＞ 99％.该产物可以用来合成光学纯的(R)-和(S)-巴氯芬.     

葡萄糖3-脱氢酶产生菌的筛选和产酶培养

从土壤中筛选分离得到1株葡萄糖3-脱氢酶产生菌,经生理生化初步鉴定为产酸克雷伯菌(Klebsiella oxyto-ca)。将菌株D8进行产酶优化培养,经过单因素法确定优化培养条件:乳糖为C源,酵母膏为N源,250 mL摇瓶装液量为50 mL,培养基的初始pH为7,33℃培养时G3DH酶比活力最高,达到1.45 U。     

葡萄糖对杜氏盐藻3-磷酸甘油脱氢酶活性的影响

杜氏盐藻是一种抗渗透能力强的单细胞绿藻,甘油在其渗透调节过程中具有重要作用。葡萄糖对杜氏盐藻细胞数量的增加效果不明显,但对盐藻细胞内甘油积累有显著促进作用,在0～15g/L范围内葡萄糖的浓度与胞内甘油积累显著相关(R2=0.9604,P=0.01);葡萄糖浓度达到15g/L时,胞内甘油积累量达到最高值7.80pg/cell,是对照的1.88倍,胞内甘油积累量与葡萄糖的消耗量极显著相关(R2=0.9982,P=0.01)。葡萄糖对盐藻细胞内总蛋白、3-磷酸甘油脱氢酶(GPDH)酶活和比活都有显著影响,在15g/L葡萄糖时这3个值达到最大值,分别是对照的1.354、4.384、3.229倍。数据显示葡萄糖浓度在15g/L时细胞内蛋白质含量增加不多,但GPDH酶活和比活却大幅度增加;葡萄糖导致的渗透压的变化可能诱导新的同功酶的合成。     

偶联羟化反应和辅酶再生体系产9α-羟基雄甾-4-烯-3,17-二酮

9α-羟基雄甾-4-烯-3,17-二酮(9-OH-AD)是一种重要的甾体药物中间体,可以用来制备β-甾酮,地塞米松和其他类固醇化合物。3-甾酮9α-羟基化酶(KSH)是由两个亚基即末端氧化亚基(KshA)和铁氧还蛋白还原亚基(KshB)构成的。在本研究中,人工合成了来源于分枝杆菌Mycobacterium sp.Strain VKM Ac-1817D的kshA和kshB基因,通过优化表达载体促进了KshA和KshB在E.coli BL21(DE3)中的可溶性表达,并探究了催化体系中KSH还原亚基和氧化亚基的最适添加比例。此外,KSH转化雄甾-4-烯-3,17-二酮(AD)为9-OH-AD的过程中需要辅酶NADH。本研究构建了羟基化反应与利用葡萄糖脱氢酶(GDH)的NADH辅酶再生反应的偶联体系。为了进一步提高转化效率,本研究进行了转化条件的优化,并采取了分批补料的策略,最终9-OH-AD产量为4.78 g/L,转化率为96.7%。此种酶介导的转化生产9-OH-AD的方法为甾体药物生产提供了一种环境友好和经济实用型的新策略。     

Biotransformation of a crizotinib intermediate using a mutant alcohol dehydrogenase of Lactobacillus kefir coupled with glucose dehydrogenase

Abstract

(S)-1-(2, 6-dichloro-3-fluorophenyl) ethanol, the key chiral intermediate of crizotinib, was prepared from 1-(2, 6-dichloro-3-fluorophenyl) ethanone using the alcohol dehydrogenases from Lactobacillus kefir (ADH-LK) with a tetrad mutant (ADH-LKM, F147L/Y190P/V196L/A202W), coupled with glucose dehydrogenase (GDH). In the present study, ADH-LKM and GDH were successfully heterologous expressed in recombinant Escherichia coli. During the regeneration of NADPH with GDH, 150?g/L substrate was totally transformed into target chiral alcohol with an enantiomeric excess value of 99.9% after 12?h at 30?°C (pH 7.0). Our study demonstrates the potential for industrial green production of the key chiral intermediate of crizotinib.     

Preparation of (S)-2,3-dichloro-1-propanol byPseudomonas sp. and its use in the synthesis of (R)-epichlorohydrin

Summary Pseudomonas sp. OS-K-29 assimilated (R)-2,3-dichloro-1-propanol preferentially as the sole source of carbon. Isolation of optically pure (S)-2,3-dichloro-1-propanol with 100% enantiomer excess (e.e.) from the racemate was done based on this bacterial assimilation using immobilized-cells of OS-K-29 with calcium-alginate. The overall examination of the reactor involved 19 batches for 50 days without loss of its activity. Highly pure (R)-epichlorohydrin with 99.5% e.e. was prepared from the (S)-2,3-dichloro-1-propanol with treatment of aqueous NaOH. This new method is simple and useful for manufacturing optically active (S)-2,3-dichloro-1-propanol and (R)-epichlorohydrin.     

Chemopreventive potential of 3-[2,6-bis(4-fluorophenyl)-3-methylpiperidin-4-ylideneamino]-2-thioxoimidazolidin-4-one on 7,12-dimethylbenz[a]anthracene (DMBA) induced hamster buccal pouch carcinogenesis

In the present work, a new bis heterocyclic compound comprising both the piperidone and thiohydantoin nuclei namely 3-[2,6-bis(4-fluorophenyl)-3-methylpiperidin-4-ylideneamino]-2-thioxoimidazolidin-4-one was synthesised and characterised with the help of mp, elemental analysis, FT-IR, MS and one-dimensional NMR (¹H and ¹³C) spectra. The inhibitory effect of 3-[2,6-bis(4-fluorophenyl)-3-methylpiperidin-4-ylideneamino]-2-thioxoimidazolidin-4-one on 7,12-dimethylbenz[a]anthracene (DMBA) induced buccal pouch carcinogenesis was investigated in Syrian male hamsters. All the hamsters that were painted with DMBA on their buccal pouches for 14 weeks developed squamous cell carcinoma. Administration of 3-[2,6-bis(4-fluorophenyl)-3-methylpiperidin-4-ylideneamino]-2-thioxoimidazolidin-4-one effectively suppressed the oral carcinogenesis initiated with the DMBA as revealed by a reduced incidence of neoplasms. Lipid peroxidation, glutathione (GSH) content and the activities of glutathione peroxidase (GPx), glutathione S-transferase (GST) were used to biomonitor the chemopreventive potential of 3-[2,6-bis(4-fluorophenyl)-3-methylpiperidin-4-ylideneamino]-2-thioxoimidazolidin-4-one. Lipid peroxidation was found to be significantly decreased, whereas GSH, GPx, GST and GGT were elevated in the oral mucosa of tumour bearing animals. Our data suggest that 3-[2,6-bis(4-fluorophenyl)-3-methylpiperidin-4-ylideneamino]-2-thioxoimidazolidin-4-one may exert its chemopreventive effects in the oral mucosa by modulation of lipid peroxidation, antioxidants and detoxification systems.     

Resolution and Synthesis of (S)-1-(2-Naphthyl)ethanol with Immobilized Pea Protein: As a New Biocatalyst

(S)-1-(2-Naphthyl)ethanol was yielded by immobilized pea (Pisum sativum L.) protein (IPP) from (R, S) 2-naphthyl ethanol (>99% ee, yield; about 50%), in which the (R)-enantiomer was selectively oxidized to 2-acetonaphthone. IPP could be reused consecutively at least three times without any decrease of yield and optical purity.     

Coexpression of a carbonyl reductase and glucose 6-phosphate dehydrogenase in Pichia pastoris improves the production of (S)-1-phenyl-1,2-ethanediol

Abstract

To develop an efficient biocatalyst to produce optically active (S)-phenyl ethanediol (PED), a carbonyl reductase SCRII and glucose 6-phosphate dehydrogenase were coexpressed intracellularly in Pichia pastoris. The recombinant enzyme PpSCRII was purified with a specific activity of 8.32 U mg^?1, over 36% higher than that of Escherichia coli SCRII. The recombinant cells P. pastoris/SCRIIG catalyzed the reduction of 2-hydroxyacetophenone to give (S)-PED with optical purity of >99% in a yield of 96.3%. The yield was improved by 19.9% and 25.7% over E. coli BL21/SCRII and Candida parapsilosis, respectively, when the reaction duration was shorted from 48 h to 24 h. When using glucose 50 g L^?1 as co-substrate, these P. pastoris/SCRIIG cells could be reused ten times and the optical purity and yield of (S)-PED kept at >99% enantiomeric excess and >85%, respectively.     

Simultaneous synthesis of enantiomerically pure (R)-1-phenylethanol and (R)-alpha-methylbenzylamine from racemic alpha-methylbenzylamine using omega-transaminase/alcohol dehydrogenase/glucose dehydrogenase coupling reaction

A simultaneous synthesis of (R)-1-phenylethanol and (R)--methylbenzylamine from racemic -methylbenzyl- amine was achievied using an -transaminase, alcohol dehydrogenase, and glucose dehydrogenase in a coupled reaction. Racemic -methylbenzylamine (100 mM) was converted to 49 mM (R)-1-phenylethanol (> 99% ee) and 48 mM (R)--methylbenzylamine (> 98% ee) in 18 h at 37 °C. This method was also used to overcome product inhibition of -TA by the ketone product in the kinetic resolution of racemic amines at high concentration.     

In Vitro Evaluation of 11C-Labeled (S)-Nicotine, (S)-3-Methyl-5-(1-Methyl-2-Pyrrolidinyl)isoxazole, and (R,S)-1-Methyl-2-(3-Pyridyl)azetidine as Nicotinic Receptor Ligands for Positron Emission Tomography Studies

Abstract: The binding characteristics of the novel ¹¹C-labeled nicotinic ligands (R,S)-1-methyl-2-(3-pyridyl) azetidine (MPA) and (S)-3-methyl-5-(1-methyl-2-pyrrolidinyl)isoxazole (ABT-418) were investigated in comparison with those of (S)-[¹¹C]nicotine in vitro in the rat brain to be able to predict the binding properties of the new ligands for positron emission tomography studies in vivo. The data from time-resolved experiments for all ligands indicated fast binding kinetics, with the exception of a slower dissociation of [¹¹C]MPA in comparison with (S)-[¹¹C]nicotine and [¹¹C]ABT-418. Saturation experiments revealed for all ligands two nicotinic receptor binding sites with affinity constants (K_D values) of 2.4 and 560 nM and binding site densities (B_max values) of 65.5 and 223 fmol/mg of protein for (S)-[¹¹C]nicotine, K_D values of 0.011 and 2.2 nM and B_max values of 4.4 and 70.7 fmol/mg of protein for [¹¹C]MPA, and K_D values of 1.3 and 33.4 nM and B_max values of 8.8 and 69.2 fmol/mg of protein for [¹¹C]ABT-418. In competing with the ¹¹C-ligands, epibatidine was most potent, followed by cytisine. A different rank order of potencies was found for (?)-nicotine, (+)-nicotine, MPA, and ABT-418 displacing each of the ¹¹C-ligands. Autoradiograms displayed a similar pattern of receptor binding for all ligands, whereby [¹¹C]MPA showed the most distinct binding pattern and the lowest nonspecific binding. We conclude that the three ¹¹C-labeled nicotinic ligands were suitable for characterizing nicotinic receptors in vitro. The very high affinity of [¹¹C]MPA to nicotinic acetylcholine receptors, its low nonspecific binding, and especially the slower dissociation kinetics of the [¹¹C]MPA from the putative high-affinity nicotinic acetylcholine receptor binding site compared with (S)-[¹¹C]nicotine and [¹¹C]ABT-418 raise the level of interest in [¹¹C]MPA for application in positron emission tomography.